Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
- PMID: 26559744
- DOI: 10.1016/S0140-6736(15)00805-3
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
Abstract
Background: Recent hypertension guidelines have reversed previous recommendations for lower blood pressure targets in high-risk patients, such as those with cardiovascular disease, renal disease, or diabetes. This change represents uncertainty about whether more intensive blood pressure-lowering strategies are associated with greater reductions in risk of major cardiovascular and renal events. We aimed to assess the efficacy and safety of intensive blood pressure-lowering strategies.
Methods: For this updated systematic review and meta-analysis, we systematically searched MEDLINE, Embase, and the Cochrane Library for trials published between Jan 1, 1950, and Nov 3, 2015. We included randomised controlled trials with at least 6 months' follow-up that randomly assigned participants to more intensive versus less intensive blood pressure-lowering treatment, with different blood pressure targets or different blood pressure changes from baseline. We did not use any age or language restrictions. We did a meta-analysis of blood pressure reductions on relative risk (RR) of major cardiovascular events (myocardial infarction, stroke, heart failure, or cardiovascular death, separately and combined), and non-vascular and all-cause mortality, end-stage kidney disease, and adverse events, as well as albuminuria and progression of retinopathy in trials done in patients with diabetes.
Findings: We identified 19 trials including 44,989 participants, in whom 2496 major cardiovascular events were recorded during a mean 3·8 years of follow-up (range 1·0-8·4 years). Our meta-analysis showed that after randomisation, patients in the more intensive blood pressure-lowering treatment group had mean blood pressure levels of 133/76 mm Hg, compared with 140/81 mm Hg in the less intensive treatment group. Intensive blood pressure-lowering treatment achieved RR reductions for major cardiovascular events (14% [95% CI 4-22]), myocardial infarction (13% [0-24]), stroke (22% [10-32]), albuminuria (10% [3-16]), and retinopathy progression (19% [0-34]). However, more intensive treatment had no clear effects on heart failure (15% [95% CI -11 to 34]), cardiovascular death (9% [-11 to 26]), total mortality (9% [-3 to 19]), or end-stage kidney disease (10% [-6 to 23]). The reduction in major cardiovascular events was consistent across patient groups, and additional blood pressure lowering had a clear benefit even in patients with systolic blood pressure lower than 140 mm Hg. The absolute benefits were greatest in trials in which all enrolled patients had vascular disease, renal disease, or diabetes. Serious adverse events associated with blood pressure lowering were only reported by six trials and had an event rate of 1·2% per year in intensive blood pressure-lowering group participants, compared with 0·9% in the less intensive treatment group (RR 1·35 [95% CI 0·93-1·97]). Severe hypotension was more frequent in the more intensive treatment regimen (RR 2·68 [1·21-5·89], p=0·015), but the absolute excess was small (0·3% vs 0·1% per person-year for the duration of follow-up).
Interpretation: Intensive blood pressure lowering provided greater vascular protection than standard regimens. In high-risk patients, there are additional benefits from more intensive blood pressure lowering, including for those with systolic blood pressure below 140 mmHg. The net absolute benefits of intensive blood pressure lowering in high-risk individuals are large.
Funding: National Health and Medical Research Council of Australia.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Comment in
-
Lower blood pressure targets: to whom do they apply?Lancet. 2016 Jan 30;387(10017):405-6. doi: 10.1016/S0140-6736(15)00816-8. Epub 2015 Nov 7. Lancet. 2016. PMID: 26559745 No abstract available.
-
ACP Journal Club. Review: More- vs less-intensive BP-lowering regimens reduce major CV events.Ann Intern Med. 2016 Feb 16;164(4):JC14. doi: 10.7326/ACPJC-2016-164-4-014. Ann Intern Med. 2016. PMID: 26882299 No abstract available.
-
Intensive blood pressure lowering - Authors' reply.Lancet. 2016 Jun 4;387(10035):2291. doi: 10.1016/S0140-6736(16)30366-X. Lancet. 2016. PMID: 27302266 No abstract available.
-
Intensive blood pressure lowering.Lancet. 2016 Jun 4;387(10035):2291. doi: 10.1016/S0140-6736(16)30688-2. Lancet. 2016. PMID: 27302267 No abstract available.
Similar articles
-
Blood pressure targets in adults with hypertension.Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD004349. doi: 10.1002/14651858.CD004349.pub3. Cochrane Database Syst Rev. 2020. PMID: 33332584 Free PMC article.
-
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.Cochrane Database Syst Rev. 2020 Sep 9;9(9):CD010315. doi: 10.1002/14651858.CD010315.pub4. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2022 Nov 18;11:CD010315. doi: 10.1002/14651858.CD010315.pub5. PMID: 32905623 Free PMC article. Updated.
-
Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: A meta-analysis.PLoS One. 2019 Apr 12;14(4):e0215362. doi: 10.1371/journal.pone.0215362. eCollection 2019. PLoS One. 2019. PMID: 30978254 Free PMC article.
-
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.Lancet. 2016 Mar 5;387(10022):957-967. doi: 10.1016/S0140-6736(15)01225-8. Epub 2015 Dec 24. Lancet. 2016. PMID: 26724178 Review.
-
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis.PLoS Med. 2012;9(8):e1001293. doi: 10.1371/journal.pmed.1001293. Epub 2012 Aug 21. PLoS Med. 2012. PMID: 22927798 Free PMC article. Review.
Cited by
-
Update of the clinical guideline for hypertension diagnosis and treatment in Iran.Clin Hypertens. 2024 Jun 1;30(1):13. doi: 10.1186/s40885-024-00269-6. Clin Hypertens. 2024. PMID: 38822442 Free PMC article.
-
Association of genetic variants related to combined lipid-lowering and antihypertensive therapies with risk of cardiovascular disease: 2 × 2 factorial Mendelian randomization analyses.BMC Med. 2024 May 20;22(1):201. doi: 10.1186/s12916-024-03407-x. BMC Med. 2024. PMID: 38764043 Free PMC article.
-
Quantifying effects of blood pressure control on neuroimaging utilization in a large multi-institutional healthcare population.PLoS One. 2024 Apr 30;19(4):e0298685. doi: 10.1371/journal.pone.0298685. eCollection 2024. PLoS One. 2024. PMID: 38687816 Free PMC article.
-
Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?Curr Cardiol Rep. 2024 Jun;26(6):623-633. doi: 10.1007/s11886-024-02055-0. Epub 2024 Apr 18. Curr Cardiol Rep. 2024. PMID: 38634964 Review.
-
Risk of Developing Hypertension in Atopic Dermatitis Patients Receiving Long-term and Low-dose Cyclosporine: A Nationwide Population-based Cohort Study.Ann Dermatol. 2024 Apr;36(2):112-119. doi: 10.5021/ad.23.099. Ann Dermatol. 2024. PMID: 38576249 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical